Ansofaxine hydrochloride
CAS No. 916918-84-8
Ansofaxine hydrochloride( LY03005 | LPM570065 )
Catalog No. M20130 CAS No. 916918-84-8
Ansofaxine (LY03005; LPM570065) is a serotonin-norepinephrine-dopamine reuptake inhibitor (IC50s: 723 763 and 491 nM respectively).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 113 | In Stock |
|
| 5MG | 164 | In Stock |
|
| 10MG | 278 | In Stock |
|
| 25MG | 509 | In Stock |
|
| 50MG | 731 | In Stock |
|
| 100MG | 1017 | In Stock |
|
| 500MG | 2034 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAnsofaxine hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionAnsofaxine (LY03005; LPM570065) is a serotonin-norepinephrine-dopamine reuptake inhibitor (IC50s: 723 763 and 491 nM respectively).
-
DescriptionAnsofaxine (LY03005; LPM570065) is a serotonin-norepinephrine-dopamine reuptake inhibitor (IC50s: 723 763 and 491 nM respectively).(In Vivo):Ansofaxine rapidly penetrates the rat striatum, converts into desvenlafaxine and exhibits larger total exposure compared with the administration of desvenlafaxine. Acute and chronic administration of oral suspension of ansofaxine increases the 5-HT, dopamine and norepinephrine levels more than the relative administration of desvenlafaxine. Unlike desvenlafaxine, acute administration of an intravenous ansofaxine solution does not induce the undesirable 90% decrease in extracellular 5-HT levels. The acute administration of ansofaxine shows a capped increase in extracellular 5-HT levels when combined with WAY-100635. Acute and chronic administration of ansofaxine reduces the immobility time more than the relative administration of desvenlafaxine.
-
In Vitro——
-
In VivoAnsofaxine rapidly penetrates the rat striatum, converts into desvenlafaxine and exhibits larger total exposure compared with the administration of desvenlafaxine. Acute and chronic administration of oral suspension of ansofaxine increases the 5-HT, dopamine and norepinephrine levels more than the relative administration of desvenlafaxine. Unlike desvenlafaxine, acute administration of an intravenous ansofaxine solution does not induce the undesirable 90% decrease in extracellular 5-HT levels. The acute administration of ansofaxine shows a capped increase in extracellular 5-HT levels when combined with WAY-100635. Acute and chronic administration of ansofaxine reduces the immobility time more than the relative administration of desvenlafaxine.
-
SynonymsLY03005 | LPM570065
-
PathwayEndocrinology/Hormones
-
Target5-HT Receptor
-
Recptorserotonin reuptake| dopamine reuptake| norepinephrine reuptake
-
Research AreaNeurological Disease
-
IndicationMajor depressive disorder
Chemical Information
-
CAS Number916918-84-8
-
Formula Weight417.97
-
Molecular FormulaC24H32ClNO3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 30 mg/mL (71.77 mM)
-
SMILESCl.CN(C)CC(c1ccc(OC(=O)c2ccc(C)cc2)cc1)C1(O)CCCCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Zhang R et al. The effects of LPM570065 a novel triple reuptake inhibitor on extracellular serotonin dopamineand norepinephrine levels in rats. PLoS One. 2014 Mar 10;9(3):e91775.
molnova catalog
related products
-
25CN-NBOH
A potent, highly selective and brain-penetrant 5-HT2A receptor agonist with Ki of 1.1 nM.
-
AVN492
AVN-492 is a potent and selective 5-HT6R Antagonist (Ki:?91 pM).
-
PRX-08066
PRX-08066 is a selective 5-hydroxytryptamine receptor 2B (5-HT2BR, IC50= 3.4 nM) antagonist that induces selective vasodilation of pulmonary arteries.
Cart
sales@molnova.com